Recent Quotes
My Watchlist
Indicators
Local Stocks
Buffalo Local Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Johnson & Johnson (NY: JNJ )

154.54 UNCHANGED
Streaming Delayed Price Updated: 7:00 PM EDT, Jun 1, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Johnson & Johnson

< Previous 1 2 3 4 5 6 7 8 9
...
62 63 Next >
AI, Tech Fuel Rebound Of Vanguard Growth ETF, Eroding Value's 2022 Outperformance
The surge of artificial intelligence (AI), the supremacy of the internet giants and expectations of the Fed's tightening cycle nearing its end are propelling growth companies to outperform value... 
Via Benzinga
3 Warren Buffett Stocks to Buy (and Never Sell)
Investors who are looking for safe retirement stocks often turn to Warren Buffett's portfolio to get a sense of which stocks to buy. 
Via InvestorPlace
Johnson & Johnson Back in Court Over Talc-Related Cancer Claims
Yesterday, Johnson & Johnson (NYSE: JNJ) faced the trial related to the lawsuit accusing its baby powder and other talc products of causing cancer.  
Via Benzinga
2 Dow Stocks to Buy More of in June
These two Dow Jones components have handed out more than 100 years of dividend hikes combined. 
Via The Motley Fool
Johnson & Johnson Unusual Options Activity
 
Via Benzinga
Expert Ratings for Johnson & Johnson
 
Via Benzinga
Check Out What Whales Are Doing With JNJ
 
Via Benzinga
Better Buy: Medtronic vs. Johnson & Johnson
Both companies are medical device leaders. 
Via The Motley Fool
5 Top Dividend Stocks to Buy in June 2023
All five of these dividend stocks are trading a cheap valuations. 
Via The Motley Fool
3 Reliable Dividend Growth Stocks to Buy Hand Over Fist in June
Adding these well-respected dividend payers to your portfolio could give you a stream of passive income that grows throughout your retirement years. 
Via The Motley Fool
3 Warren Buffett Stocks That Are Screaming Buys in June
These time-tested Buffett stocks are clear-as-day values hiding in plain sight. 
Via The Motley Fool
Nvidia Becomes Ninth Company To Hit $1 Trillion Market Cap — Who Could Be Next To Join Elusive Club?
A surge in price for shares of Nvidia Corporation (NASDAQ: NVDA) after the company’s quarterly earnings results and guidance has put the semiconductor company in the elusive $1 trillion market... 
Via Benzinga
Kenvue's Growth Forecast: Exploring The Future Of Johnson & Johnson's Carve-Out
 
Via Benzinga
7 Undervalued Blue-Chip Stocks to Buy for June 2023
These top undervalued blue-chip stocks offer a significant amount of upside as we get into the second half of 2023. 
Via InvestorPlace
Buy the Dip On These Warren Buffett Stocks
You'll want to follow Buffett's lead and hold on to these stocks forever. 
Via The Motley Fool
3 Dow Stocks Poised for a Roaring Relief Rally
Here are some compelling Dow stocks to buy if you believe the market may be on the cusp of a relief rally this summer. 
Via InvestorPlace
Want Passive Income Forever? Buy These 2 Magnificent Stocks Now
You can take these companies' dividends straight to the bank. 
Via The Motley Fool
A Challenger to J&J's Top Blockbuster Is on the Way. Here's What You Need to Know.
Biotech-giant Amgen aims to launch a rival. 
Via The Motley Fool
Value Stocks Hit 15-Month Low Against Growth As AI Fuels Tech's Vengeance Over 2022's Rate-Hike-Induced Market Fall
Value stocks fell to a seven-month low in relation to growth stocks, already lagging by more than 20% year to date on the heels of an AI-related rally propelling equities in the technology sector.  
Via Benzinga
Wall Street's Most Accurate Analysts Say Buy These 3 Health Care Stocks With Over 3% Dividend Yields
During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high... 
Via Benzinga
New Data Out Of Cleveland Clinic Shows BioSig PURE EP May Be Used For More Precise Approach For $6 Billion Annual Atrial Fibrillation Market
Cleveland Clinic researchers presented data from three new studies involving BioSig Technologies’ (NASDAQ: BSGM) proprietary PURE EP Platform at the annual Heart Rhythm 2023 meeting in Ne 
Via Benzinga
Ranked: Who Made The Most U.S. Unicorn Acquisitions Since 1997?
Unicorn acquisitions are driven by two factors: the rate at which new unicorns are minted, and the climate for M&A transactions more broadly. 
Via Talk Markets
7 Safe-Haven Stocks to Buy for Protection From a U.S. Debt Default Disaster
With so many uncertainties about federal financial obligations, investors should target these safe-haven stocks for debt default. 
Via InvestorPlace
Buying These 2 Stocks Is a Good Way to Hedge Against a Market Crash
Both companies have produced consistent revenue growth and predictable profitability. 
Via The Motley Fool
Rain Oncology Shares Plummet: Company Discloses Disappointing Cancer Study Data After Delaying Readout
Rain Oncology Inc (NASDAQ: RAIN) announced topline Phase 3 MANTRA data of milademetan in patients with  
Via Benzinga
Immix Biopharma's Subsidiary Says Investigational CAR T Therapy Shows 100% Response Rate In Amyloidosis
Immix Biopharma Inc's (NASDAQ: IMMX) subsidiary Nexcella Inc announced updated AL Amyloidosis clinical data from its ongoing Phase 1b/2a NEXICART-1 study of its BCMA-targeted chimeric antigen receptor... 
Via Benzinga
Got $1,000? 5 Buffett Stocks to Buy and Hold Forever
Warren Buffett owns many stocks, but these five have solid growth potential. 
Via The Motley Fool
3 Relatively Safe Stocks to Buy if a Recession Is on the Way
If the economy falters, these stocks should hold up better than most. 
Via The Motley Fool
WHO Recommends New COVID Booster Shots To Target XBB Variants, Despite Slower Uptake
An advisory group for the World Health Organization said the current crop of shots should be updated to target the currently dominant XBB strains for the 
Via Benzinga
FDA Approves First Oral Treatment For Crohn's Disease, Making Seventh Approval For AbbVie's Rinvoq
The FDA approved AbbVie Inc's (NASDAQ: ABBV) Rinvoq (upadacitinib) for moderately to severely active Crohn's disease patients with inadequate response or intolerance to  
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
62 63 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.